Page last updated: 2024-10-17

lactic acid and Retinitis

lactic acid has been researched along with Retinitis in 2 studies

Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.

Retinitis: Inflammation of the RETINA. It is rarely limited to the retina, but is commonly associated with diseases of the choroid (CHORIORETINITIS) and of the OPTIC DISK (neuroretinitis).

Research Excerpts

ExcerptRelevanceReference
"The therapeutic effects of betamethasone phosphate (BP) encapsulated in biocompatible and biodegradable blended nanoparticles of poly(lactic acid) (PLA) homopolymers and PEG-block-PLA copolymers (stealth nanosteroids) were examined in an experimental autoimmune uveoretinitis (EAU) model in Lewis rats."7.77Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. ( Akiyama, G; Higaki, M; Ishihara, T; Sakai, T; Tsuneoka, H, 2011)
" In this study, we evaluated the effects of intravenously administered poly(lactic acid) nanoparticles encapsulating betamethasone phosphate (BP-PLA NPs) on experimental autoimmune uveoretinitis (EAU) in Lewis rats."7.73Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. ( Higaki, M; Ishihara, T; Kitahara, K; Kohno, H; Matsushima, M; Mizushima, Y; Saito, S; Sakai, T, 2006)
"The therapeutic effects of betamethasone phosphate (BP) encapsulated in biocompatible and biodegradable blended nanoparticles of poly(lactic acid) (PLA) homopolymers and PEG-block-PLA copolymers (stealth nanosteroids) were examined in an experimental autoimmune uveoretinitis (EAU) model in Lewis rats."3.77Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. ( Akiyama, G; Higaki, M; Ishihara, T; Sakai, T; Tsuneoka, H, 2011)
" In this study, we evaluated the effects of intravenously administered poly(lactic acid) nanoparticles encapsulating betamethasone phosphate (BP-PLA NPs) on experimental autoimmune uveoretinitis (EAU) in Lewis rats."3.73Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. ( Higaki, M; Ishihara, T; Kitahara, K; Kohno, H; Matsushima, M; Mizushima, Y; Saito, S; Sakai, T, 2006)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sakai, T2
Ishihara, T2
Higaki, M2
Akiyama, G1
Tsuneoka, H1
Kohno, H1
Saito, S1
Matsushima, M1
Mizushima, Y1
Kitahara, K1

Other Studies

2 other studies available for lactic acid and Retinitis

ArticleYear
Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis.
    Investigative ophthalmology & visual science, 2011, Mar-18, Volume: 52, Issue:3

    Topics: Animals; Autoimmune Diseases; Betamethasone; Biocompatible Materials; Biological Availability; Delay

2011
Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate.
    Experimental eye research, 2006, Volume: 82, Issue:4

    Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Betamethasone; Choroid; Delayed-Action Prepa

2006